Salignostics Overview
Pro stress-test →Salignostics is an R&D company that focuses on the development of saliva-based rapid diagnostics tests, addressing a critical gap in non-invasive healthcare diagnostics. The company's first commercially successful product is Salistick, a saliva-based pregnancy test, with more than 500,000 units sold and ordered after launch in Israel and the UK (early 2024). The platform enables faster, cheaper, and more accessible testing across multiple disease categories.
Strategic Profile
Pro stress-test →Salignostics has assembled a team of experts in saliva research and tech and business development, with 15 years of experience in the field. The company has launched three innovative saliva-based diagnostic products: Salistick, SaliCov (COVID-19), and Salicomb (collection device), with Salistick now accessible in over 1,500 retail locations and recognized with a 2023 Time Magazine Best Invention award. The company plans to expand its portfolio to address streptococcus, STDs, and cardiac risk indicators.
Competitive Landscape
Pro stress-test →Salignostics competes in rapid point-of-care diagnostics against established players like Abbott, Quidel, and newer entrants focused on non-invasive testing. Competitors include traditional pregnancy test manufacturers (urine-based), COVID-19 test providers, and emerging saliva diagnostic startups. Salignostics' differentiation rests on its proprietary saliva platform enabling faster, lower-cost, and non-invasive testing across multiple indications.
Industry Context
Salignostics operates in Rapid point-of-care diagnostics.
Key facts
Founded: Not publicly disclosed; leadership has 15+ years industry experience · Headquarters: Jerusalem, Israel · Employees: 10–50 · Revenue: Estimated $5M–$25M (private company; based on 500K+ Salistick units and early-stage commercialization)